The Tavneos story keeps getting worse, and it now raises a question that should concern every company with a marketed drug: how quickly can a drug’s evidence base come apart in public?
Follow the arc. In June the FDA flagged patient deaths and asked Amgen to pull Tavneos voluntarily. Amgen fought back, commissioning an independent analysis from Duke researchers to defend it. Last week the European CHMP recommended revoking the drug’s marketing authorization. And now a top medical journal has retracted the pivotal study that supported the approval in the first place. That is about as complete a reversal as you see for a drug that made it all the way to market.
Tavneos treats ANCA associated vasculitis, a serious autoimmune disease where patients genuinely need steroid sparing options. The clinical stakes for those patients are real. But the trajectory here is one directional, and Amgen’s room to defend the franchise is shrinking by the week.
On a much brighter note, BeOne Medicines showed that its BTK inhibitor Brukinsa plus rituximab cut the risk of progression or death by 43% versus standard chemotherapy in frontline mantle cell lymphoma. No chemo. No rituximab maintenance. It is the first Phase 3 to test a chemotherapy free regimen as a new frontline standard in MCL. And the broader industry picture continues to brighten: layoffs slowed again in Q2, and the first half closed with 52 M&A deals.
The Pivotal Study Behind Tavneos Has Been Retracted
What Happened: A leading medical journal retracted the pivotal trial that supported approval of Amgen’s Tavneos (avacopan).
Why a Retraction Is Different From Everything That Came Before
We have covered Tavneos at several points this year. The FDA’s voluntary removal request on June 17. The CHMP’s revocation recommendation last week. Each of those was a regulatory action based on post market safety data—the agencies concluded that patient deaths raised questions about whether the drug’s risks outweighed its benefits.
A study retraction is something else entirely. It goes to the root. The pivotal study is the clinical trial data that the FDA and European regulators evaluated when they decided to approve Tavneos in the first place. When that study is retracted by the journal that published it, the scientific foundation of the approval is called into question. Regulators approved the drug based on evidence. The custodian of that evidence has now pulled it.
For Amgen, the practical question is whether Tavneos can remain on the market in any jurisdiction. Defending a drug against a post market safety signal is difficult but not unprecedented—companies negotiate label changes, add warnings, restrict distribution, and sometimes keep the drug available for patients who have no alternatives. Defending a drug after the underlying pivotal study has been retracted is a fundamentally different challenge. The evidence base that justified the benefit side of the risk benefit equation no longer stands as published.
ANCA associated vasculitis patients are caught in the middle of this. The disease attacks blood vessels and can damage kidneys, lungs, and other organs. Treatment has historically relied on corticosteroids, which work but carry a heavy burden of side effects over the long term—bone loss, diabetes, weight gain, immune suppression. Tavneos provided a way to reduce that corticosteroid dependence. If it is pulled from the market, these patients lose one of the few targeted treatment options available to them.
The broader lesson for the industry is about evidence integrity as an ongoing obligation rather than a box checked at the time of approval. A journal does not retract a study lightly. Retraction typically means the editors and peer reviewers have identified problems with the data, the analysis, or the conduct of the trial that are serious enough to undermine the study’s conclusions. When that happens to a pivotal study—the specific trial that regulators evaluated to determine whether a drug should be approved—the regulatory foundation of the approval is compromised.
This does not mean every retraction leads to drug withdrawal. Regulators weigh the totality of evidence, including post market data, additional studies, and real world experience. But when the safety monitoring has already flagged deaths, and the pivotal study has been retracted, the weight of evidence shifts heavily against the drug’s continued marketing.
For Amgen, which also commissioned the Duke independent analysis to defend Tavneos, the retraction makes that defense much harder. An independent analysis of the pivotal data loses its persuasive power when the journal that published the pivotal data no longer stands behind it.
BeOne’s Brukinsa Wins in Frontline Mantle Cell Lymphoma Without Chemotherapy
What Happened: BeOne Medicines reported positive topline results from the Phase 3 MANGROVE trial, showing Brukinsa (zanubrutinib) plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab in adults with previously untreated mantle cell lymphoma (HR 0.57, 95% CI 0.43 to 0.76, p<0.0001).
What Makes This Result Important
This is the first Phase 3 trial to test a chemotherapy free regimen as a new frontline standard in mantle cell lymphoma. That distinction matters. MCL has historically meant chemotherapy for newly diagnosed patients. Bendamustine plus rituximab has been a go to regimen, and it works, but it comes with the toxicities that every oncologist and patient associates with chemo: nausea, immune suppression, fatigue, and the cumulative burden of extended treatment cycles.
The Brukinsa regimen replaces bendamustine with a BTK inhibitor (oral, taken daily) and drops rituximab maintenance entirely. BeOne says this spares patients roughly two years of infusions that the standard regimen requires. A 43% reduction in the risk of progression or death, delivered through an oral pill plus a limited course of rituximab, is a compelling case for changing how newly diagnosed MCL is treated.
Safety was consistent with both drugs’ known profiles, and no new signals emerged. That matters because the BTK inhibitor class has faced safety scrutiny in other settings. J&J and AbbVie previously withdrew Imbruvica’s MCL indication in the United States after confirmatory data disappointed, which hangs over any BTK inhibitor filing in this space.
The OS Question
Overall survival was immature at this analysis but trended in Brukinsa’s favor. The final analysis will test OS formally. That number carries extra weight here precisely because of the Imbruvica withdrawal. Regulators and payers will want to see that the PFS win translates into a survival benefit, or at the very least does not raise the survival concerns that troubled the class before.
MANGROVE also serves as the confirmatory trial for Brukinsa’s 2019 accelerated approval in previously treated MCL. A strong confirmatory result resolves the regulatory obligation and converts the conditional approval into a full one. BeOne plans global regulatory submissions in the second half of 2026.
The Bigger Picture: Chemo Keeps Getting Pushed Out
The BTK inhibitor class has been steadily displacing chemotherapy across B cell malignancies for years. Chronic lymphocytic leukemia went chemo free years ago. Waldenström’s macroglobulinemia followed. Now MANGROVE pushes the same trend into frontline mantle cell lymphoma. Each new data set narrows the role of chemotherapy in blood cancers and expands the role of targeted oral therapies that patients tolerate better and can take at home rather than in an infusion center.
This is the same trajectory we have tracked across solid tumor oncology this year—treatments moving toward convenience and away from toxicity. ADCs replacing broad chemotherapy in breast cancer, bladder cancer, and lung cancer. Oral GLP 1s replacing injectable regimens in obesity. Now oral BTK inhibitors replacing IV chemo in blood cancer. The direction is consistent across the industry: give patients effective treatment that does less harm and fits better into their lives.
Layoffs Slow and Dealmaking Booms: The Industry Health Check
Two data points from this week tell a consistent story about where the industry stands heading into the second half of the year.
Layoffs Are Easing
Biopharma layoffs slowed again in the second quarter, extending a recovery that started last fall, according to a Fierce Biotech analysis. After more than 42,000 job cuts across the industry in 2025, the easing pace is a meaningful signal. The brutal stretch that saw Takeda cut 4,500, Gilead cut 87% of Arcellx staff, Genentech restructure deep enough to lose a 30 year veteran, and dozens of smaller companies halve or quarter their workforces appears to be subsiding.
That does not mean the restructuring is over. Companies are still right sizing around core priorities. BioCryst just closed its entire discovery center. enGene halved its workforce. The pattern is specific: companies are cutting where they have excess capacity or programs that do not fit the strategic focus, and hiring where they need to integrate acquisitions, build commercial teams, or expand clinical operations. The net headcount in biopharma is not necessarily growing. But the pace of reductions is no longer accelerating.
52 Deals in the First Half
BioSpace reported that the first half of 2026 closed with 52 M&A deals. Put that together with the mood at BIO International, which attendees described as overwhelmingly positive, and the sector looks healthier than it has since before the 2022 downturn.
The caveats are familiar: FDA unpredictability (Replimune accepted, Capricor surprised with an adcomm, Tavneos collapsing), drug pricing pressure (MFN framework, Medicare Bridge, European reforms), and the geopolitical tension around China (COINS Act, Decree No. 834). But the fundamentals have turned. Cash reserves are deep. Biotech valuations leave room for deals. The patent cliff forces acquisition activity. IPOs reopened with 13 companies raising more than $4 billion. And the companies producing positive clinical data are being rewarded with capital faster than at any point in recent memory (Definium raised $805 million within 48 hours of a Phase 3 win).
The structural drivers are intact for the second half. The question is not whether deals will continue but whether the pace can sustain or accelerate through the Section 232 tariff deadline (July 31), the Revolution approval cycle (Truist projects Q3), and the Lilly Investment Community Meeting (December 7). The Medicare Bridge launched yesterday. Retatrutide TRIUMPH 2 and TRIUMPH 3 readouts are expected this year. GSK’s Nuvalent lung cancer drugs are under FDA review. Merck’s sac TMT global filing is expected. And the search for a permanent FDA commissioner continues to drag on with no nominee announced. The catalysts are dense, the momentum is real, and the industry enters the second half looking healthier than it has in years.
Lonza Expands a U.S. Biopharma Collaboration
Lonza announced an expanded strategic collaboration with an unnamed U.S. based biopharmaceutical company. Details were thin—the partner, the scope, and the financial terms were not disclosed. But the deal continues a busy stretch for the CDMO sector, which has been consolidating and expanding capacity throughout 2026.
The CDMO story connects to everything else happening in the industry. When M&A is running at record pace and companies are advancing ADCs, cell therapies, mRNA vaccines, and molecular glues simultaneously, someone has to manufacture all of those products. The CDMOs with the right capabilities—biologics, conjugation chemistry, cell and gene therapy production—are seeing the strongest demand. Lonza is one of the largest and most capable CDMOs in the world. An expanded collaboration with a U.S. biopharma company, even with details undisclosed, signals continued demand for the kind of specialized manufacturing that the current pipeline requires.
Strategic Themes
1. The Tavneos Arc Is a Warning About Post Market Evidence Risk
FDA scrutiny. Voluntary withdrawal request. CHMP revocation recommendation. And now a pivotal study retraction. Each step compounds the last. The Tavneos story is not just about one drug from one company. It is a case study in how a marketed drug’s evidence base can erode to the point where continued marketing becomes untenable. Every company with a post market safety monitoring obligation should study this sequence and stress test their own evidence integrity.
2. Chemotherapy Keeps Getting Pushed Out of Blood Cancer Treatment
MANGROVE is the latest data set in a trend that has been building for years. CLL went chemo free. Waldenström’s followed. Now frontline mantle cell lymphoma has a chemo free Phase 3 winner. Each displacement narrows the role of cytotoxic chemotherapy and expands the role of targeted oral therapies that patients tolerate better. The OS data will be the final test for Brukinsa in this setting, but the direction of travel is clear.
3. The Industry Is Moving From Survival Mode to Growth Mode
Layoffs slowing after 42,000 cuts in 2025. Fifty two deals in the first half. Thirteen IPOs raising $4 billion. The mood at BIO described as the most optimistic in years. The biotech sector spent 2022 through 2024 in a downturn defined by rising rates, frozen IPOs, and defensive cost cutting. The first half of 2026 looks like the other side of that cycle. The risks have not disappeared. But the balance has shifted from contraction to expansion across most of the industry.
4. The Second Half Starts With Momentum and Multiple Catalysts
Medicare Bridge launched yesterday. Section 232 tariffs hit July 31. Revolution’s approval is projected for Q3. Retatrutide TRIUMPH 2 and TRIUMPH 3 readouts are expected this year. Lilly’s Investment Community Meeting is December 7. GSK’s Nuvalent lung cancer drugs are under FDA review. Merck’s sac TMT global filing is expected. And somewhere in there, the administration will need to find a permanent FDA commissioner. The catalysts are dense and the momentum is real. The second half of 2026 has the potential to be as consequential as the first.
Frequently Asked Questions
What happened with Tavneos?
A leading medical journal retracted the pivotal study that supported Tavneos (avacopan) approval. This follows the FDA’s voluntary removal request over patient deaths (June) and the European CHMP’s recommendation to revoke marketing authorization (last week). Amgen’s options to defend the drug are narrowing.
What is the MANGROVE result?
Brukinsa (zanubrutinib) plus rituximab cut the risk of progression or death by 43% (HR 0.57, p<0.0001) versus bendamustine plus rituximab in frontline mantle cell lymphoma. First Phase 3 to test a chemo free frontline standard in MCL. Drops rituximab maintenance, sparing patients about two years of infusions. OS was immature but trending favorably. BeOne plans H2 2026 filings.
Are layoffs still happening?
The pace slowed again in Q2, extending a recovery from last fall. After 42,000 plus cuts across biopharma in 2025, the easing is meaningful. Restructuring continues at specific companies, but the industry wide contraction appears to be subsiding.
How many deals happened in H1?
Fifty two M&A deals, per BioSpace. The first half was the most active dealmaking stretch in years, driven by patent cliff urgency, deep cash reserves, and a productive pipeline of acquisition targets.
What is the Lonza deal?
An expanded strategic collaboration with an unnamed U.S. biopharma company. Details were not disclosed. Continues the busy CDMO stretch driven by demand for specialized manufacturing in ADCs, cell therapies, and biologics.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
The Tavneos Unwind. We trace the complete arc from FDA scrutiny to pivotal study retraction, assess what it means for post market safety enforcement, and evaluate Amgen’s remaining options in both the U.S. and European markets.
Chemo Free Frontline MCL. We analyze why MANGROVE matters for the BTK inhibitor class, what the Imbruvica MCL withdrawal means for Brukinsa’s regulatory path, and why overall survival data will determine whether this result changes practice permanently.
Industry Health Check. We compile the first half numbers—52 deals, layoff trends, IPO proceeds, BIO sentiment—and assess what the structural drivers mean for the second half deal calendar and the broader sector recovery.
Plus: Lonza CDMO analysis, Medicare Bridge first day tracking, Revolution filing watch, and the full H2 catalyst calendar.
About BioMed Nexus
BioMed Nexus delivers institutional grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep dive analyses cut through the noise to deliver the strategic insights that drive better decision making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
